Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome

被引:36
|
作者
Emmens, Johanna E. [1 ]
ter Maaten, Jozine M. [1 ]
Matsue, Yuya [1 ]
Metra, Marco [2 ]
O'Connor, Christopher M. [3 ]
Ponikowski, Piotr [4 ]
Teerlink, John R. [5 ,6 ]
Cotter, Gad [7 ]
Davison, Beth [7 ]
Cleland, John G. [8 ]
Givertz, Michael M. [9 ]
Bloomfield, Daniel M. [10 ]
Dittrich, Howard C. [11 ]
Todd, John [12 ]
van Veldhuisen, Dirk J. [1 ]
Hillege, Hans L. [1 ,13 ]
Damman, Kevin [1 ]
van der Meer, Peter [1 ]
Voors, Adriaan A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands
[2] Univ Brescia, Brescia, Italy
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Med Univ, Clin Mil Hosp, Wroclaw, Poland
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] San Francisco VA Med Ctr, San Francisco, CA USA
[7] Momentum Res, Durham, NC USA
[8] Univ Hull, Kingston Upon Hull, Yorks, England
[9] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[10] Merck Res Labs, Rahway, NJ USA
[11] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA
[12] Singulex Inc, Alameda, CA USA
[13] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands
关键词
Plasma KIM-1; Heart failure; Prognosis; TUBULAR DAMAGE; DISEASE; ROLOFYLLINE; ANTAGONIST; MORTALITY; BIOMARKER; KIM-1; RISK;
D O I
10.1002/ejhf.426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsUrinary kidney injury molecule-1 (KIM-1) is a marker of tubular damage and associated with worse outcome in heart failure (HF). Plasma KIM-1 has not been described in HF. Methods and resultsIn a renal mechanistic cohort of 120 chronic HF patients, we established the association between plasma KIM-1, renal invasive haemodynamic parameters {renal blood flow ([I-131]hippuran clearance) and measured glomerular filtration rate (GFR; [I-125]iothalamate)} and urinary tubular damage markers. The association between plasma KIM-1, plasma creatinine, and clinical outcome was further explored in a cohort of 2033 acute HF patients. Median plasma KIM-1 was 171.5pg/mL (122.8-325.7) in chronic (n = 99) and 295.1pg/mL (182.2-484.2) in acute HF (n = 1588). In chronic HF, plasma KIM-1 was associated with GFR (P < 0.001), creatinine, and cystatin C. Plasma KIM-1 was associated with urinary N-acetyl--d-glucosaminidase (NAG), but not with other urinary tubular damage markers. Log plasma KIM-1 predicted adverse clinical outcome after adjustment for age, gender, and GFR [hazard ratio (HR) 1.94, 95% confidence interval (CI) 1.07-3.53, P = 0.030]. Statistical significance was lost after correction for NT-proBNP (HR 1.61, 95% CI 0.81-3.20, P = 0.175). In acute HF, higher plasma KIM-1 levels were associated with higher creatinine, lower albumin, and presence of diabetes. Log plasma KIM-1 predicted 60-day HF rehospitalization (HR 1.27, 95% CI 1.03-1.55, P = 0.024), but not 180-day mortality or 60-day death or renal or cardiovascular rehospitalization. ConclusionsPlasma KIM-1 is associated with glomerular filtration and urinary NAG, but not with other urinary tubular damage markers. Plasma KIM-1 does not predict outcome in chronic HF after correction for NT-proBNP. In acute HF, plasma KIM-1 predicts HF rehospitalization in multivariable analysis.
引用
收藏
页码:641 / 649
页数:9
相关论文
共 50 条
  • [1] Urinary kidney injury molecule-1 in renal disease
    Moresco, Rafael N.
    Bochi, Guilherme V.
    Stein, Carolina S.
    De Carvalho, Jose A. M.
    Cembranel, Bibiana M.
    Bollick, Yanai S.
    CLINICA CHIMICA ACTA, 2018, 487 : 15 - 21
  • [2] Kidney injury molecule-1 in renal disease
    Waanders, Femke
    van Timmeren, Mirjan M.
    Stegeman, Coen A.
    Bakker, Stephan J. L.
    van Goor, Harry
    JOURNAL OF PATHOLOGY, 2010, 220 (01) : 7 - 16
  • [3] Kidney Injury Molecule-1 Correlates With Kidney Function in Heart Allograft Recipients
    Przybylowski, P.
    Malyszko, J.
    Kozlowska, S.
    Malyszko, J. S.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (08) : 3061 - 3063
  • [4] Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure)
    Grodin, Justin L.
    Perez, Antonio L.
    Wu, Yuping
    Hernandez, Adrian F.
    Butler, Javed
    Metra, Marco
    Felker, G. Michael
    Voors, Adriaan A.
    McMurray, John J.
    Armstrong, Paul W.
    Califf, Robert M.
    Starling, Randall C.
    O'Connor, Christopher M.
    Tang, W. H. Wilson
    JACC-HEART FAILURE, 2015, 3 (10) : 777 - 785
  • [5] Kidney injury molecule-1 as a biomarker of acute kidney injury in renal transplant recipients
    Perco, Paul
    Oberbauer, Rainer
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2008, 4 (07): : 362 - 363
  • [6] Kidney injury molecule-1 in kidney disease
    Yin, Caixia
    Wang, Ningning
    RENAL FAILURE, 2016, 38 (10) : 1567 - 1573
  • [7] Kidney injury molecule-1 inhibits metastasis of renal cell carcinoma
    Lee, Jasper C.
    Yotis, Demitra M.
    Lee, Ji Yun
    Sarabusky, Marie A.
    Shrum, Bradly
    Champagne, Audrey
    Ismail, Ola Z.
    Tutunea-Fatan, Elena
    Leong, Hon S.
    Gunaratnam, Lakshman
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [8] Urinary kidney injury molecule-1 levels in renal stone patients
    Balasar, Mehmet
    Piskin, Mehmet Mesut
    Topcu, Cemile
    Demir, Lutfi Saltuk
    Gurbilek, Mehmet
    Kandemir, Abdulkadir
    Ozturk, Ahmet
    WORLD JOURNAL OF UROLOGY, 2016, 34 (09) : 1311 - 1316
  • [9] Circulating kidney injury molecule-1 as a biomarker of renal parameters in diabetic kidney disease
    Gohda, Tomohito
    Kamei, Nozomu
    Koshida, Takeo
    Kubota, Mitsunobu
    Tanaka, Kanako
    Yamashita, Yoshinori
    Adachi, Eri
    Ichikawa, Saki
    Murakoshi, Maki
    Ueda, Seiji
    Suzuki, Yusuke
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (02) : 435 - 440
  • [10] Relationships of kidney injury molecule-1 with renal function and cardiovascular risk factors in the general population
    Egli, Peter
    Aeschbacher, Stefanie
    Bossard, Matthias
    Eggimann, Lucien
    Blum, Steffen
    Meyre, Pascal
    Bargetzi, Laura
    Estis, Joel
    Todd, John
    Risch, Martin
    Risch, Lorenz
    Conen, David
    CLINICA CHIMICA ACTA, 2018, 478 : 13 - 17